

# Clinical Outcomes in Children Living With Human Immunodeficiency Virus Treated for Nonsevere Tuberculosis in the SHINE Trial

Chishala Chabala,<sup>1,2,3,6</sup> Eric Wobudeya,<sup>4,6</sup> Marieke M. van der Zalm,<sup>5</sup> Monica Kapasa,<sup>2</sup> Priyanka Raichur,<sup>6,6</sup> Robert Mboizi,<sup>4</sup> Megan Palmer,<sup>5,6</sup> Aarti Kinikar,<sup>6,6</sup> Syed Hissar,<sup>7</sup> Veronica Mulenga,<sup>1,2,6</sup> Vidya Mave,<sup>6,6</sup> Philippa Musoke,<sup>4</sup> Anneke C. Hesselning,<sup>5,6</sup> Helen McIlleron,<sup>3,6</sup> Diana Gibb,<sup>8,6</sup> Angela Crook,<sup>8,a</sup> and Anna Turkova,<sup>8,a</sup> on behalf of the SHINE Trial Team<sup>b</sup>

<sup>1</sup>Department of Paediatrics, School of Medicine, University of Zambia, Lusaka, Zambia; <sup>2</sup>Children's Hospital, University Teaching Hospitals, Lusaka, Zambia; <sup>3</sup>Faculty of Health Sciences, Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa; <sup>4</sup>Mulago Hospital, Makerere University–John Hopkins Hospital Research Collaboration, Kampala, Uganda; <sup>5</sup>Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa; <sup>6</sup>Byramjee Jeejeebhoy Medical College, Johns Hopkins University Clinical Research Site, Pune, India; <sup>7</sup>Indian Council of Medical Research, National Institute for Research in Tuberculosis, Chennai, India; and <sup>8</sup>Institute of Clinical Trials and Methodology, Medical Research Council–Clinical Trials Unit at University College London, London, United Kingdom

**Background.** Children living with human immunodeficiency virus (HIV, CLWH) are at high risk of tuberculosis (TB) and face poor outcomes, despite antiretroviral therapy (ART). We evaluated outcomes in CLWH and children not living with HIV treated for nonsevere TB in the SHINE trial.

**Methods.** SHINE was a randomized trial that enrolled children aged <16 years with smear-negative, nonsevere TB who were randomized to receive 4 versus 6 months of TB treatment and followed for 72 weeks. We assessed TB relapse/recurrence, mortality, hospitalizations, grade  $\geq 3$  adverse events by HIV status, and HIV virological suppression in CLWH.

**Results.** Of 1204 children enrolled, 127 (11%) were CLWH, of similar age (median, 3.6 years; interquartile range, 1.2, 10.3 versus 3.5 years; 1.5, 6.9;  $P = .07$ ) but more underweight (weight-for-age  $z$  score,  $-2.3$ ; (3.3,  $-0.8$  versus  $-1.0$ ;  $-1.8$ ,  $-0.2$ ;  $P < .01$ ) and anemic (hemoglobin, 9.5 g/dL; 8.7, 10.9 versus 11.5 g/dL; 10.4, 12.3;  $P < .01$ ) compared with children not living with HIV. A total of 68 (54%) CLWH were ART-naïve; baseline median CD4 count was 719 cells/mm<sup>3</sup> (241–1134), and CD4% was 16% (10–26). CLWH were more likely to be hospitalized (adjusted odds ratio, 2.4; 1.3–4.6) and to die (adjusted hazard ratio [aHR], 2.6; 95% confidence interval [CI], 1.2 to 5.8). HIV status, age <3 years (aHR, 6.3; 1.5, 27.3), malnutrition (aHR, 6.2; 2.4, 15.9), and hemoglobin <7 g/dL (aHR, 3.8; 1.3, 11.5) independently predicted mortality. Among children with available viral load (VL), 45% and 61% CLWH had VL <1000 copies/mL at weeks 24 and 48, respectively. There was no difference in the effect of randomized treatment duration (4 versus 6 months) on TB treatment outcomes by HIV status ( $P$  for interaction = 0.42).

**Conclusions.** We found no evidence of a difference in TB outcomes between 4 and 6 months of treatment for CLWH treated for nonsevere TB. Irrespective of TB treatment duration, CLWH had higher rates of mortality and hospitalization than their counterparts not living with HIV.

**Clinical Trials Registration.** ISRCTN63579542.

**Keywords.** tuberculosis; children living with HIV; viral suppression; mortality; adverse events.

Children living with human immunodeficiency virus (HIV, CLWH) are disproportionately affected by tuberculosis (TB). Annually, approximately 1.3 million children develop TB, resulting in 214 000 deaths; most cases go undiagnosed and untreated [1, 2]. Among children and adolescents aged <15 years

who are dying from TB, 10% are living with HIV [3]. Antiretroviral therapy (ART) confers significant benefits, reducing the incidence of TB in CLWH [4, 5]. However, despite good immune recovery and viral suppression following ART initiation, the risk of developing TB remains higher in CLWH compared with their counterparts not living with HIV [6], and ART may take up to 2 years to fully reach its potential for protection against TB [4].

Without ART, CLWH have 5 times higher risk of death compared with their peers not living with HIV [5, 7, 8]. Diagnostic challenges hamper early identification of TB in CLWH, leading to frequent late presentation with severe TB and advanced HIV disease, particularly in high TB endemic settings [9, 10]. HIV/TB coinfection is associated with worse HIV treatment outcomes and is among several factors that contribute to virological failure in individuals living with HIV in sub-Saharan Africa [11].

Received 08 December 2023; editorial decision 28 March 2024; published online 9 April 2024

<sup>a</sup>A. C. and A. T. share joint senior authorship.

<sup>b</sup>Study team members are listed in the Notes section.

Correspondence: C. Chabala, Department of Paediatrics, School of Medicine, University of Zambia, P.O. Box 50110, Ridgeway, Lusaka, Zambia (cchabala@gmail.com).

Clinical Infectious Diseases<sup>®</sup>

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

<https://doi.org/10.1093/cid/ciae193>

Children concurrently treated for TB and HIV had 10% to 20% lower rates of viral suppression, with this risk persisting during the first year of ART treatment [12–14].

Treatment of TB in CLWH is complicated by drug–drug interactions and overlapping toxicities between antiretroviral and rifampicin-based anti-TB regimens. In low- and middle-income countries, treatment options for children with HIV/TB are limited, and rifabutin, which is frequently used in high-income countries to substitute rifampicin, is not available. Overlapping toxicities from cotreatment increase the risk of adverse events (AEs) that may affect adherence and TB and HIV treatment outcomes [15–17].

In the SHINE trial, children with nonsevere TB, randomized to receive shorter (4-month) or standard (6-month) treatment, were followed up for 72 weeks and assessed for unfavorable outcomes [18]. The trial found that 4 months was noninferior to the standard 6 months of treatment in children with nonsevere TB [19]. Here, we report on clinical outcomes in CLWH compared with children not living with HIV and describe HIV virological suppression at 24 and 48 weeks in CLWH.

## METHODS

### Study Design and Population

The SHINE trial, a noninferiority trial, enrolled children aged <16 years with nonsevere TB following written informed consent from parents/guardians. Children of known HIV status with symptomatic, nonsevere, smear-negative, intrathoracic TB or peripheral lymphadenitis were included. Based on the Wiseman criteria [19, 20], nonsevere respiratory TB was defined as respiratory disease confined to a single lobe (opacification of <1 lobe) with none of the following on chest X ray (CXR): cavities, miliary disease pattern, complex pleural effusions, and significant airway compression. TB diagnosis was made by site clinicians based on clinical features, TB contact history, CXR findings, and mycobacterial test results.

We conducted a secondary analysis of TB treatment outcomes, mortality, hospitalizations, and grade  $\geq 3$  AEs in CLWH compared with children not living with HIV. TB treatment outcome was defined as unfavorable if any of the following occurred: death (all-cause), treatment failure, TB treatment change, restart or extension, TB recurrence, or loss to follow-up by 72 weeks [19]. Other clinical outcomes were death, hospitalization by 72 weeks, grade  $\geq 3$  AEs during and up to 30 days after treatment, and viral suppression at 24 and 48 weeks in CLWH. AE severity was graded following established criteria [21].

### Study Procedures and Interventions

Eligible children with presumptive TB were screened and had a clinical evaluation including TB symptoms, contact history, and a physical examination. Details of TB evaluation and initiation procedures are published elsewhere [18, 19]. At

enrollment, respiratory samples and/or lymph node aspirates (if clinically indicated) were obtained for smear microscopy, Xpert MTB/RIF (Xpert, Cepheid), and mycobacterial culture. CXRs were performed to inform diagnostic certainty and TB disease severity classification and to establish trial eligibility. In addition, using standard criteria [18, 22], a separate independent endpoint review committee (ERC), blinded to treatment allocation, reviewed clinical events suggestive of treatment failure or TB recurrence and all deaths.

At enrollment, blood samples were obtained for hematology and chemistry in all children, and CD4 cell count and HIV-1 viral load (VL) testing (if it was part of the standard of care in the country) were obtained for CLWH. Children were seen at week 2, every 4 weeks until week 28, and then every 3 months up to week 72. At each visit, clinical evaluations were performed to detect new AEs, treatment failures, or recurrence of TB. CD4 cell count was repeated at weeks 24 and 48. HIV-1 VL was repeated at the intervals specified by national recommendations. Acute illnesses, hospitalizations, and deaths were documented throughout follow-up.

Anti-TB treatment (rifampicin, isoniazid, pyrazinamide, and/or ethambutol) was administered according to randomization arm (4 or 6 months duration) and dosed per World Health Organization (WHO)–recommended weight bands using fixed-dose combination tablets (Macleods Pharmaceuticals, India) [23].

ART was provided in accordance with WHO 2016 treatment guidelines [24] and respective national recommendations. ART included 2 nucleoside reverse-transcriptase inhibitors (lamivudine with abacavir, zidovudine, or tenofovir disoproxil fumarate) plus efavirenz (EFV) or lopinavir/ritonavir (LPV/r). For anti-TB cotreatment, LPV/r was superboosted (if single-formulated ritonavir was available) or the daily dose of LPV/r was doubled.

### Statistical Analyses

Baseline characteristics were compared using  $\chi^2$  and *t* tests. Heterogeneity of the effect of the randomized duration of treatment on TB outcomes assessed at the end of treatment was formally tested between CLWH and children not living with HIV by inclusion of a treatment by HIV status interaction term in a binary risk difference model. The interaction was tested by use of a likelihood ratio test to compare models with and without the interaction term, with  $P < .1$  considered evidence of a different effect (4 versus 6 months) between CLWH and children not living with HIV. For this comparison, we included outcomes from week 16 onward (before week 16, treatment in the randomized groups was the same).

Logistic regression and Cox proportional hazards (CPH) models were fitted to investigate baseline predictors of clinical outcomes including age, sex, randomization arm, clinical sites, weight-for-age *z* score (WAZ), and TB disease characteristics in CLWH versus children not living with HIV. Mortality was fitted as a time-to-event outcome (CPH models, summary

**Table 1. Baseline Characteristics of Participants by Human Immunodeficiency Virus Status**

Characteristic	Living with HIV (n = 127)	Not Living With HIV (n = 1077)	Total (n = 1204)	P Value <sup>a</sup>
Age, y	3.6 (1.2, 10.3)	3.5 (1.5, 6.9)	3.5 (1.5, 7.0)	.07
Female	63 (49.6)	520 (48.3)	583 (48.4)	.78
Weight-for-age zscore	-2.3 (-3.3, -0.8)	-1.0 (-1.8, -0.2)	-1.0 (-1.9, 0.3)	<.01 (t test)
Hemoglobin count, g/dL	9.5 (8.7, 10.9)	11.5 (10.4, 12.3)	11.3 (10.1, 12.2)	<.01 (t test)
Alanine aminotransferase	20.2 (13.8, 35.2)	15.0 (12.0, 20.8)	15.7 (12.0, 21.4)	<.01 (t test)
Site of disease, <sup>b</sup> n (%)				
Pulmonary only	74 (58.3)	730 (67.8)	804 (66.8)	<.01
Pulmonary and lymph node	53 (41.7)	300 (27.9)	353 (29.3)	...
Lymph node only	0 (0)	40 (3.7)	40 (3.3)	...
Other	0 (0)	7 (0.7)	7 (0.6)	...
TB status				
Bacteriologically confirmed	8 (6.3)	157 (14.6)	165 (13.7)	.01
Unconfirmed	95 (74.8)	698 (64.1)	1039 (85.9)	...
Unlikely	24 (18.9)	222 (20.6)	246 (20.4)	...
Anti-TB drug dosing weight band, kg				
3.0 ≤ 3.9	2 (1.6)	1 (0.1)	3 (0.3)	<.01
4.0 ≤ 7.9	35 (27.6)	145 (13.5)	180 (15.0)	...
8.0 ≤ 11.9	29 (22.8)	284 (26.4)	313 (26.0)	...
12.0 ≤ 15.9	10 (7.9)	231 (21.5)	241 (20.0)	...
16.0 ≤ 24.9	31 (24.4)	266 (24.7)	297 (24.7)	...
≥25.0	20 (15.8)	150 (13.9)	170 (14.1)	...
Site/Country				
Zambia	91 (71.6)	273 (25.3)	364 (30.2)	<.001
Uganda	31 (24.4)	345 (32.0)	376 (31.2)	...
South Africa	5 (3.9)	310 (28.8)	315 (26.2)	...
India	0 (0)	149 (13.8)	149 (12.4)	...
Randomization arm				
4 m	65 (51.2)	537 (49.9)	602 (50.0)	...
6 m	62 (48.8)	540 (50.1)	602 (50.0)	...

Data presented as number of participants (%) or median (interquartile range).

Abbreviations: HIV, human immunodeficiency virus; TB, tuberculosis.

<sup>a</sup>P value from  $\chi^2$  test unless otherwise stated.

<sup>b</sup>Intrathoracic lymph node was classified as pulmonary TB; peripheral lymph node disease without any respiratory symptoms or abnormal chest X-ray findings was classified as lymph node disease.

measure hazard ratio [HR]); other outcomes were fitted as binary (logistic regression, summary measure odds ratio [OR]). All multivariable models included HIV status, age, country, TB confirmation, and randomized duration of treatment. Other factors found to be significant ( $P < .1$ ) in the univariable model were also included.

In the CLWH cohort, timing of ART, ART regimens, and viral suppression <1000 mL copies/mL at 24 and 48 weeks were assessed.

### Ethical Considerations

The study was approved by the ethics committees and regulatory authorities in Zambia, Uganda, South Africa, and India and by the sponsor, the University College London Ethics Committee.

### RESULTS

Of the 1204 children enrolled in the trial, 127 (11%) were CLWH, the majority from Zambia (91, 72%) and Uganda (31, 24%;

Table 1). Of CLWH, two-thirds (65%) had advanced or severe HIV (before the TB episode); median (interquartile range [IQR]) baseline CD4% and CD4 cell counts were 16% (10, 26) and 719 cells/mm<sup>3</sup> (241, 1134), respectively. At enrollment, 68 (54%) of the CLWH were ART-naïve (Table 2). Baseline HIV1 VL was available for 23 children; median (IQR) baseline HIV1 VL was 89 973 (1864, 587 977); and 4 (17%) had VL <1000. Most started ART within 2–8 weeks after starting TB treatment; 2 died before ART initiation, and ART status data were missing for 9.

CLWH were of similar median (IQR) age compared with children not living with HIV (3.6 years, 1.2, 10.3 versus 3.5 years, 1.5–6.9 years) but were more underweight (WAZ: -2.3; -3.3, -0.8 versus -1.0; -1.8, -0.2;  $P < .001$ ) and had lower hemoglobin counts (9.5 g/dL, 8.7, 10.9 versus 11.5 g/dL, 10.4, 12.3;  $P < .001$ ). CLWH had a higher proportion of mixed (pulmonary and lymph node) TB disease (42% versus 28%,  $P < .001$ ) compared with children not living with HIV. Overall, 165 (14%) children had

bacteriologically confirmed TB by Xpert *Mycobacterium tuberculosis*/rifampin or culture, with a significantly smaller proportion (8, 6%) in CLWH compared with children not living with HIV (165, 15%;  $P < .01$ ; Table 1).

Overall, 92% of the children in the trial had favorable TB treatment outcomes. In the modified intention-to-treat population, the adjusted absolute risk difference of an unfavorable outcome (4-month versus 6-month arm) was  $-4.3\%$  (in favor of 4-months, 95% confidence interval [CI],  $-14.9$  to  $6.2$  in

CLWH) and  $0.0\%$  (95% CI,  $-1.8$  to  $1.8$ ) in children not living with HIV, with no heterogeneity in the effect of randomized duration of treatment (4 versus 6 months of antituberculosis treatment) on TB treatment outcomes by HIV status (test for interaction,  $P = .42$ ; Table 3).

Unfavorable TB treatment events were more frequent in CLWH ( $n = 24$ , 19%) compared with children not living with HIV ( $n = 69$ , 6%; adjusted HR [aHR], 2.4; 1.3, 4.2; Table 4). Across both groups, in addition to HIV status, age  $< 3$  years (aHR, 3.0; 95% CI, 1.7 to 5.2), being underweight (WAZ,  $\leq -2$ ; aHR, 1.8; 95% CI, 1.1 to 2.9), and anemic hemoglobin  $< 7\text{g/dL}$ ; aHR, 4.6; 95% CI, 2.1 to 10.3) were independently predictive of unfavorable TB outcomes (Supplementary Table 1).

Of 113 children with at least 1 hospitalization in 72 weeks of follow-up, 18 (14%) were among CLWH compared with 95 (9%) among children not living with HIV. Overall, the risk of hospitalization was more than twice as high among CLWH compared with children not living with HIV (aHR, 2.4; 95% CI, 1.3 to 4.6; Table 4). In both groups, age  $< 3$  years (aOR, 1.8; 95% CI, 1.2 to 2.9) also predicted hospitalization (Supplementary Table 1).

Thirty-one of the 1204 (3%) deaths in the trial (Uganda, 17 of 376 (5%); Zambia, 13 of 364 (4%); South Africa, 1 (<1%) of 315; India, 0 (0%) of 149; 12 (39%) occurred before week 16. Thirteen of 127 (10%) were among CLWH and 18 of 1077 (2%) were among children not living with HIV (aHR, 2.6; 95% CI, 1.2 to 5.8). Pneumonia ( $n = 6$ ) followed by seizures ( $n = 2$ ), septicemia ( $n = 2$ ), diarrheal disease ( $n = 2$ ), and hypotension/shock and trauma ( $n = 3$ ) were the common causes of death (Supplementary Table 2). As adjudicated by the ERC, blinded to trial arm, 7 of 13 (54%) deaths among CLWH and 6 of 18 (33%) among children not living with HIV were due to TB. The median (IQR) time to death was 4.6 months (2.1, 7.0) shorter in CLWH than in children not living with HIV (6.6 months, 1.8, 8.8; Table 4, Supplementary Figure 1). Independent of HIV status, age  $< 3$  years (aHR, 6.3; 95% CI,

**Table 2. Clinical Characteristics of Participants Living With Human Immunodeficiency Virus**

Clinical Characteristic (n = 127)	Frequency, n (%)
<b>Human immunodeficiency virus treatment status at baseline</b>	
Naive	68 (53.5)
On ART	59 (46.5)
<b>World Health Organization immunological classification<sup>a</sup> (n = 88)</b>	
Not significant	21 (24.4)
Mild	8 (9.3)
Advanced	8 (9.3)
Severe	49 (57.0)
<b>CD4 count (n = 95), cell/mm<sup>3</sup></b>	
$< 200$	19 (20.0)
$\geq 200$ –350	10 (10.5)
$\geq 350$ –500	7 (7.4)
$\geq 500$	59 (62.1)
<b>CD4% (n = 86)</b>	
$< 15$	34 (39.5)
$\geq 15$	52 (60.5)
<b>ART regimen (n = 116)</b>	
Efavirenz-based	60 (51.7)
Lopinavir-based	43 (37.1)
Nevirapine-based	13 (11.2)

Abbreviation: ART, antiretroviral therapy.

<sup>a</sup>World Health Organization case definitions of human immunodeficiency virus (HIV) for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children [25].

**Table 3. Subgroup Analysis of Tuberculosis Outcomes and Randomized Treatment Duration by Human Immunodeficiency Virus Status**

Subgroup parameters assessed	Children Living With HIV		Children Not Living With HIV		Total
	4 Months	6 Months	4 Months	6 Months	
Total randomized	65	62	537	540	1204
Unassessable <sup>a</sup>	6	8	24	21	59
Did not reach week 16	4	5	11	11	31
Favorable	55 (93%)	48 (89%)	501 (98%)	507 (98%)	1111 (97%)
Unfavorable	4 (7%)	6 (11%)	12 (2%)	12 (2%)	34 (3%)
Total assessable	59	54	513	519	1145
Difference from control in unfavorable rate	$-4.3\%$	...	$0.03\%$	...	...
95% confidence interval	( $-14.9$ to $6.2$ )	...	( $-1.8$ to $1.9$ )	...	...

Test for interaction:  $P$  value = .42. Test for interaction compares the effects (risk difference) of treatment duration on tuberculosis (TB) outcomes, comparing children living with HIV and children not living with HIV.

Abbreviation: HIV, human immunodeficiency virus.

<sup>a</sup>Reasons for unassessable include not reaching week 16 and late exclusions for drug-resistant TB.

**Table 4. Mortality, Hospitalizations, and Nonfatal Grade  $\geq 3$  Adverse Events by Human Immunodeficiency Virus Status**

Clinical Outcome	Living With HIV n = 127	Not Living With HIV n = 1077	Adjusted Hazard Ratio <sup>a</sup> (95% CI)
<i>Tuberculosis treatment outcome</i>			
Unfavorable	24 (18.9)	69 (6.4)	2.4 (1.3 to 4.2)
Favorable	103 (81.1)	1008 (93.6)	...
<i>Mortality</i>			
Dead	13 (10.2)	18 (1.7)	2.6 (1.2 to 5.8)
Alive	114 (89.8)	1059 (98.3)	
Adjusted Odds Ratio <sup>b</sup> (95% CI)			
<i>Hospitalization</i>			
Yes	18 (14.2)	95 (8.8)	2.4 (1.3 to 4.6)
No	109 (85.8)	982 (91.2)	...
<i>Adverse event (grade <math>\geq 3</math>)</i>			
Yes	24 (18.9)	71 (6.6)	4.4 (2.3 to 8.5)
No	103 (81.1)	982 (93.4)	...

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus.

<sup>a</sup>Adjusted for age, hemoglobin count, weight-for-age z score, bacteriological confirmation, country, and randomized tuberculosis (TB) treatment duration.

<sup>b</sup>Adjusted for age, weight-for-age z score, bacteriological confirmation, site of TB disease, hemoglobin count, country, and randomized TB treatment duration.

1.5 to 27.3), being underweight (aHR, 6.2; 95% CI, 2.4 to 15.9), and being anemic (aHR, 3.8; 95% CI, 1.3 to 11.5) had higher risks of mortality (Supplementary Table 1).

Seventy-four children experienced at least 1 grade 3 or 4 AE, reported up to 30 days after the last dose of TB treatment. Grade  $\geq 3$  AEs reported in  $\geq 5\%$  were pneumonia or chest infection (29, 25%), deranged liver function (11, 10%), diarrheal diseases (7, 6%), and epilepsy or seizures (6, 5%). CLWH were more likely to experience a grade  $\geq 3$  AE compared with children not living with HIV (aHR, 4.6; 95% CI, 2.1 to 9.9; Table 4). In both groups, children aged  $< 3$  years had a higher risk of experiencing a grade  $\geq 3$  AE than older children (aOR, 2.1; 95% CI, 1.2 to 3.6; Supplementary Table 1).

HIV-1 VL results were available for 65 of 119 (55%) and 82 of 115 (71%) CLWH at week 24 and at week 48, respectively; 45% (week 24) and 61% (week 48) had VL  $< 1000$  copies/mL. A higher proportion of children who received EFV-based ART were virologically suppressed compared with those on LPV/r-based ART at week 48 (29 of 41, 71%) versus 20 of 40 (50%;  $P = .056$ ).

## DISCUSSION

Our findings show that overall unfavorable TB treatment outcomes were more frequent in CLWH compared with children not living with HIV. However, when randomized duration of TB treatment was compared, there was no difference in unfavorable outcomes between 4 and 6 months in CLWH. Thus, there was no evidence to suggest that CLWH with nonsevere TB needed longer treatment duration than children not living with HIV and that both groups can receive the shorter 4 months of treatment. CLWH were at higher risk of hospitalizations and grade  $\geq 3$  AEs compared with those not living with HIV. Mortality was infrequent in the entire study population;

however, as expected, the risk was higher in CLWH, and time to death was sooner. Viral suppression in CLWH was suboptimal with only 61% having VL  $< 1000$  at 48 weeks. Children on LPV/r-based ART had a trend toward worse VL responses compared with those on EFV-based regimens.

Our results concur with those from the many pediatric studies that have reported worse TB treatment outcomes in CLWH compared with children not living with HIV, particularly in the presence of severe TB disease [26–31]. We enrolled only children with nonsevere TB, and despite overall excellent treatment outcomes, HIV coinfection increased the risk of unfavorable TB outcomes, as observed in cohorts with a wider spectrum of disease [7, 8, 26, 27]. Similarly, the risks of hospitalization and death were significantly higher in CLWH. Despite this, the rate of mortality in the SHINE study was similar to or lower than the reported mortality in children below 5 years in the respective countries in 2020 (India, 4%; South Africa, 3%; Uganda, 4%; and Zambia, 6%) [32]. Among CLWH,  $> 10\%$  died compared with  $< 2\%$  in children not living with HIV. Mortality rates for children with TB vary widely, from  $< 1\%$  in the Netherlands to 13% in Nigeria, with higher rates reported in children with severe forms of TB [7, 8, 26–29, 33]. Observational studies of children with HIV/TB coinfection have reported higher mortality rates of 10% to 20%, with worse outcomes in ART-naïve populations [5, 9, 10, 34]. In our cohort, less than half of the CLWH were on ART at the time of TB diagnosis and more than 80% were on ART by the end of the intensive phase. While higher ART coverage reduces the risk of mortality in CLWH with TB, it does not eliminate it [35, 36]. Deaths in individuals with TB often occur in the first few months of treatment, particularly in those living with HIV where rapid progression of TB can occur even in the absence of immune compromise [35–37].

There were few grade  $\geq 3$  AEs observed in the trial. However, CLWH had a 5-fold risk of experiencing an AE. After chest infections, elevation of liver enzymes was the most common treatment-related AE [19]. Transient and asymptomatic transaminitis is commonly observed in children on TB treatment and represents hepatic adaptation to TB treatment and is often reversible [38].

Our study showed that children aged  $<3$  years, with or without HIV, faced a significant risk of experiencing unfavorable TB outcomes, hospitalization, death, and AEs. Of note, among CLWH, a higher proportion were underweight and anemic compared with those not living with HIV. Being underweight was an independent predictor of poor clinical outcomes, emphasizing the critical role of inadequate nutrition in contributing to unfavorable outcomes regardless of HIV status in children with TB. Younger age and undernutrition were previously identified as risk factors for TB-associated mortality. Our study emphasizes that this remains relevant even in children with nonsevere TB disease [35, 39, 40]. Furthermore, anemia (hemoglobin  $<7\text{g/dL}$ ) independently predicted unfavorable TB outcomes, hospitalizations, and mortality, irrespective of HIV status. Anemia is frequently observed in children from low- and middle-income countries, often associated with undernutrition [41], and it commonly complicates HIV [42]. Notably, it is a prevalent comorbidity with TB and linked to poor TB treatment outcomes [43, 44].

Among CLWH with available HIV-1 VLs, viral suppression was suboptimal after 1 year of follow-up. This could be due to insufficient duration of ART since only half of the children were established on ART at the time of enrollment and ART initiation times varied. Previous studies suggested that children cotreated for TB around the time of ART initiation had low rates of virological suppression [12–14, 45]. Another possible reason could be biased selective targeting of VL testing in children with suspected nonadherence to ART. We observed a trend toward better viral suppression in children who received EFV-based ART compared with those on LPV/r-based ART. South African studies reported lower rates of viral suppression in children who received ritonavir-boosted LPV/r-based ART who were cotreated for TB [13, 14]. For children aged  $<3$  years, superboosted LPV/r is the preferred strategy to overcome the interaction with rifampicin. However, not all sites implemented LPV/r superboosting during the SHINE trial due to the nonavailability of single-formulated ritonavir. In Zambia, double-dosing of LPV/r or switching to EFV in children aged  $\geq 3$  years was practiced for rifampicin cotreatment in the absence of single-formulated ritonavir. However, LPV/r double-dosing was previously associated with suboptimal lopinavir concentrations with rifampicin cotreatment [46]. Drug resistance mutations to protease inhibitors are infrequent despite virological failures, suggesting that other treatment-related factors (in particular, adherence difficulties) are likely the main contributors to nonviral suppression [47], especially since pediatric formulations of LPV/r are not palatable and require twice-daily

administration [13, 48, 49]. The currently recommended dolutegravir (DTG)-based ART, which is associated with high rates of viral suppression and excellent safety, is considered the preferred treatment option for CLWH with HIV/TB despite requiring twice-daily dosing in children with HIV/TB [50]. DTG was not available for pediatric use at the time of the trial.

This study has several limitations including lack of generalizability to children with severe TB disease. The trial aimed to evaluate the noninferiority of 4 months versus 6 months of treatment in children with nonsevere TB; therefore, CLWH with severe TB were excluded. Second, assessment of viral suppression in CLWH may have been affected by missing VL results. In this pragmatic trial, VLs were measured per national recommendations, which did not mandate frequent VL testing. Nevertheless, our findings align with observations in other cohorts that suggest suboptimal VL suppression in CLWH diagnosed with TB and starting ART [12, 13]. Despite these limitations, this trial had a considerable number of CLWH and excellent follow-up of up to 72 weeks, allowing comprehensive documentation of the clinical outcomes. TB diagnoses were thoroughly evaluated using well-defined criteria and independent expert review [20, 22].

We found no evidence of a difference between 4 and 6 months of treatment for CLWH being treated for nonsevere TB. Acknowledging that the interaction test was underpowered and the analysis can only be considered exploratory, it was nevertheless reassuring that along with all the other subgroup analyses performed, the results were consistent with the overall trial findings [19]. Benefits of shortening TB treatment include improved treatment adherence, minimal losses to follow-up, and fewer AEs associated with prolonged TB treatment. Efforts should focus on equipping health services and providers with the capacity to appropriately determine TB disease severity and identify children who can benefit from the shorter regimen. In addition, patient-centered management should include the identification of potential risk factors, such as anemia and undernutrition, that are likely to impact treatment outcomes. Early HIV diagnosis, access to ART, and comprehensive patient care that includes nutritional support can improve outcomes and reduce the risk of poor outcomes in CLWH.

## CONCLUSIONS

In conclusion, our study highlights that CLWH with nonsevere TB had a higher risk of poor clinical outcomes compared with children not living with HIV. We found no significant differences in TB treatment outcomes between CLWH and children not living with HIV who received 4 versus 6 months of TB treatment, providing reassurance that CLWH can receive shorter 4 months of TB treatment if they have nonsevere TB.

## Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted

materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

## Notes

**Acknowledgments.** The authors thank the children who participated in the SHINE trial and their caregivers; the nursing, pharmacy, and laboratory staff; all those who advised, volunteered, or otherwise supported community engagement at the trial sites; and the members of the trial steering committee, the endpoint review committee, and the independent data and safety monitoring committee for their contributions, including oversight of the safety of the trial.

SHINE Trial Team:

*SHINE Trial Team UK Medical Research Council, Clinical Trials Unit at University College London:* Louise Choo, Genevieve Wills, Margaret J. Thomason, Jaqueline Teera, Ellen Owen-Powell, Kristen LeBeau, David Baptiste, Charlotte McGowan, Moira Spyer. *University Teaching Hospital, Children's Hospital, Lusaka, Zambia:* Joyce Lungu, Kevin Zimba, Khozya Zyambo, Chalilwe Chungu, Chimuka Tembo, Sharon Kunda, Ellen Shingalili, Semy Zulu, Terence Chipoya, Habulembe Mwanakalanga, Elias Chambela, Jessy M. Hankombo, Mox Malama Kalumbi, Daniel Chola, Stephen Malama. *Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda:* Winnie Nansamba, Mark Ssenyonga, Willy Ssengooba, Gerald Businge. *Desmond Tutu TB Centre, Stellenbosch University, South Africa:* Jessica Workman, Anne-Marie Demers, Simon SchAAF, Robert Gie, Elisabetta Walters, Warren Zimri, Graeme Hoddinott, Anneen van Deventer, Pierre Goussard, Julie Morrison. *Byramjee Jeejeebhoy Government Medical College, Pune, India:* Aparna Nijampurkar, Sameer Khan. *Indian Council of Medical Research, National Institute for Research in Tuberculosis, Chennai, India:* Bency Joseph, Perumal Kannabiran Bhavani, G. Prathiksha, Dhanaraj Baskaran, N. S. Gomathi, V. Mythily, Hemanth Kumar, Silambu Chelvi, L. Sekar, Luke Hanna, K. Ramesh, Hema Latha, S. Bharathi, Parveen Banu, Dino Xavier, Manjith Kumar, K. Guru, Sasi Kumar, A. Kesavan, A. Gunasundari, G. Mangalambal, Valarmathi Nagarajan, Shakeela Shankar, R. Selvi, S. Vaishnavi, Krishna Yadav, R. Supriya, Hema Giranab, A. Seetha, Stella Mary, S. Gopika, S. Rohini, M. Revathy. *Institute of Child Health and Hospital for Children, Chennai, India:* Sarath Balaji, S. Elilarasi. *Government Stanley Medical College and Hospital, Chennai, India:* J. Ganesh, M. A. Aravind. *Local site monitors:* Sylvia Mulambo, Hope Mwanyungwi, Dharati Tapse, Manasi Sane, Amina Abdullah, Sarah Nakalanzi, Cynthia Mukisa Williams. *Radboud University Medical Center, Nijmegen, the Netherlands:* Rob Aarnoutse. *University of York, York, United Kingdom:* Paul Revall, James Love-Koh, Simon Walker. *SHINE Trial Steering Committee members:* Peter Mugenyi (chair), Janet Darbyshire, Polly Clayden, Peter Donald, Varinder Singh, Malgosia Grzemska (replaced by Sabine Verkuilj and Annemieke Brands in March 2020), Soumya Swaminathan. *SHINE Independent Data Monitoring Committee members:* Tim Peto (Chair), Alwyn Mwinga, Katherine Fielding. *SHINE Endpoint Review Committee members:* Stephen M. Graham (Chair), Steven B. Welch, James A. Seddon, Elizabeth Whittaker, Suzanne Anderson, Louis Grandjean.

**Financial support.** This work was supported by a grant (MR/L004445/1) from the Medical Research Council (UK MRC), the Department for International Development, the Wellcome Trust, National Institute for Health Research (UK) under the Joint Global Health Trials Scheme. Additional support was by the UK MRC (core support grant; MC\_UU\_12023/26 and MC\_UU\_12023/27). TB Alliance provided support for trial drugs purchases.

**Potential conflicts of interest.** C. C., E. W., S. H., Vi. M., and A. C. H. report institutional funding to participate as SHINE trial sites from the UK MRC—Clinical Trials at University College, London, through a prime grant award from UK MRC, Wellcome Trust, and Department for International Development (grant MR/L004445/1). A. T., A. K., and D. G. report a COVID 19 Grant Extension Allocation award 181573 from UK Research Innovation. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

## References

1. World Health Organization. Global tuberculosis report 2023. Geneva, Switzerland: World Health Organization, 2023.
2. Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of tuberculosis mortality in children: a mathematical modelling study. *Lancet Glob Health* 2017; 5:e898–906.
3. UNAIDS. UNAIDS data 2022. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS, 2022.
4. Dodd PJ, Prendergast AJ, Beecroft C, Kampmann B, Seddon JA. The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis. *Thorax* 2017; 72:559–75.
5. Mandalakas AM, Kay AW, Bacha JM, et al. Tuberculosis among children and adolescents at HIV treatment centers in sub-Saharan Africa. *Emerg Infect Dis* 2020; 26:2933–43.
6. Kay AW, Rabie H, Maleche-Obimbo E, Sekadde MP, Cotton MF, Mandalakas AM. HIV-associated tuberculosis in children and adolescents: evolving epidemiology, screening, prevention and management strategies. *Pathogens* 2021; 11:33.
7. Osman M, Lee K, Du Preez K, Dunbar R, Hesselning AC, Seddon JA. Excellent treatment outcomes in children treated for tuberculosis under routine operational conditions in Cape Town, South Africa. *Clin Infect Dis* 2017; 65:1444–52.
8. Onyango DO, Yuen CM, Masini E, Borgdorff MW. Epidemiology of pediatric tuberculosis in Kenya and risk factors for mortality during treatment: a national retrospective cohort study. *J Pediatr* 2018; 201:115–21.
9. Marcy O, Tejiokem M, Msellati P, et al. Mortality and its determinants in antiretroviral treatment-naïve HIV-infected children with suspected tuberculosis: an observational cohort study. *Lancet HIV* 2018; 5:e87–95.
10. Buck WC, Olson D, Kabue MM, et al. Risk factors for mortality in Malawian children with human immunodeficiency virus and tuberculosis co-infection. *Int J Tuberc Lung Dis* 2013; 17:1389–95.
11. Agegehu CD, Techane MA, Mersha AT, Atalell KA. Burden and associated factors of virological failure among people living with HIV in sub-Saharan Africa: a systematic review and meta-analysis. *AIDS Behav* 2022; 26:3327–36.
12. Humphrey JM, Genberg BL, Keter A, et al. Viral suppression among children and their caregivers living with HIV in western Kenya. *J Int AIDS Soc* 2019; 22:e25272.
13. Zanoni BC, Phungula T, Zanoni HM, France H, Feeney ME. Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART. *AIDS* 2011; 25:49–55.
14. Reitz C, Coovadia A, Ko S, et al. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. *J Infect Dis* 2010; 201:1121–31.
15. McIlleron H, Chirehwa MT. Current research toward optimizing dosing of first-line antituberculosis treatment. *Expert Rev Anti Infect Ther* 2019; 17:27–38.
16. Rabie H, Decloedt EH, Garcia-Prats AJ, et al. Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. *Expert Opin Pharmacother* 2017; 18:589–98.
17. Cerrone M, Bracchi M, Wasserman S, et al. Safety implications of combined antiretroviral and anti-tuberculosis drugs. *Expert Opin Drug Saf* 2020; 19:23–41.
18. Chabala C, Turkova A, Thomason MJ, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. *Trials* 2018; 19:237.
19. Turkova A, Wills GH, Wobudeya E, et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. *N Engl J Med* 2022; 386:911–22.
20. Wiseman CA, Gie RP, Starke JR, et al. A proposed comprehensive classification of tuberculosis disease severity in children. *Pediatr Infect Dis J* 2012; 31:347–52.
21. NIH Division of Microbiology and Infectious Diseases. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Available at: <https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf>. Accessed 12 March 2024.
22. Graham SM, Cuevas LE, Jean-Philippe P, et al. Clinical case definitions for classification of intrathoracic tuberculosis in children: an update. *Clin Infect Dis* 2015; 61(Suppl 3):S179–87.
23. World Health Organization. Statement on the use of child-friendly fixed-dose combinations for the treatment of TB in children. 2017. Available at: <https://www.who.int/publications/m/item/statement-on-the-use-of-child-friendly-fixed-dose-combinations-for-the-treatment-of-tb-in-children>. Accessed 24 April 2024.
24. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva, Switzerland: World Health Organization, 2016.

25. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland: World Health Organization, 2007.
26. Siamisang K, Rankoane-Pono G, Madisa TM, et al. Pediatric tuberculosis outcomes and factors associated with unfavorable treatment outcomes in Botswana, 2008–2019: a retrospective analysis. *BMC Public Health* 2022; 22:2020.
27. Belay GM, Wubneh CA. Childhood tuberculosis treatment outcome and its association with HIV co-infection in Ethiopia: a systematic review and meta-analysis. *Trop Med Health* 2020; 48:7.
28. Gafar F, Van't Bovenind-Vrubleuskaya N, Akkerman OW, Wilffert B, Alffenaar JC. Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands. *Eur Respir J* 2019; 54:1901402.
29. Moon TD, Nacarapa E, Verdu ME, et al. Tuberculosis treatment outcomes among children in rural southern Mozambique: a 12-year retrospective study. *Pediatr Infect Dis J* 2019; 38:999–1004.
30. Onyango DO, Yuen CM, Cain KP, Ngari F, Masini EO, Borgdorff MW. Reduction of HIV-associated excess mortality by antiretroviral treatment among tuberculosis patients in Kenya. *PLoS One* 2017; 12:e0188235.
31. Osman M, du Preez K, Seddon JA, et al. Mortality in South African children and adolescents routinely treated for tuberculosis. *Pediatrics* 2021; 147:e2020032490.
32. UNICEF. Child survival—under-five mortality. Available at: <https://data.unicef.org/topic/child-survival/under-five-mortality/>. Accessed 2 August 2023.
33. Adejumo OA, Daniel OJ, Adebayo BI, et al. Treatment outcomes of childhood TB in Lagos, Nigeria. *J Trop Pediatr* 2016; 62:131–8.
34. Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. *BMC Pediatr* 2008; 8:1.
35. Jenkins HE, Yuen CM, Rodriguez CA, et al. Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis. *Lancet Infect Dis* 2017; 17: 285–95.
36. Nicholson TJ, Hoddinott G, Seddon JA, et al. A systematic review of risk factors for mortality among tuberculosis patients in South Africa. *Syst Rev* 2023; 12:23.
37. Adamu AL, Aliyu MH, Galadanci NA, et al. Deaths during tuberculosis treatment among paediatric patients in a large tertiary hospital in Nigeria. *PLoS One* 2017; 12:e0183270.
38. Gafar F, Arifin H, Jornalis YD, et al. Antituberculosis drug-induced liver injury in children: incidence and risk factors during the two-month intensive phase of therapy. *Pediatr Infect Dis J* 2019; 38:50–3.
39. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intrathoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. *Int J Tuberc Lung Dis* 2004; 8:392–402.
40. Vonasek BJ, Rabie H, Hesselting AC, Garcia-Prats AJ. Tuberculosis in children living with HIV: ongoing progress and challenges. *J Pediatric Infect Dis Soc* 2022; 11(Supplement\_3):S72–8.
41. Sun J, Wu H, Zhao M, Magnussen CG, Xi B. Prevalence and changes of anemia among young children and women in 47 low- and middle-income countries, 2000–2018. *EClinicalMedicine* 2021; 41:101136.
42. Abioye AI, Andersen CT, Sudfeld CR, Fawzi WW. Anemia, iron status, and HIV: a systematic review of the evidence. *Adv Nutr* 2020; 11:1334–63.
43. Abaynew Y, Ali A, Taye G, Shenkut M. Prevalence and types of anemia among people with tuberculosis in Africa: a systematic review and meta-analysis. *Sci Rep* 2023; 13:5385.
44. Luo M, Liu M, Wu X, et al. Impact of anemia on prognosis in tuberculosis patients. *Ann Transl Med* 2022; 10:329–329.
45. Afrane AKA, Goka BQ, Renner L, et al. HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study. *BMC Infect Dis* 2021; 21: 731.
46. McIlleron H, Ren Y, Nuttall J, et al. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. *Antivir Ther* 2011; 16:417–21.
47. Bircher RE, Ntamungiro AJ, Glass TR, et al. High failure rates of protease inhibitor-based antiretroviral treatment in rural Tanzania—a prospective cohort study. *PLoS One* 2020; 15:e0227600.
48. Musiime V, Fillekes Q, Kekitiinwa A, et al. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in African HIV-infected children. *J Acquir Immune Defic Syndr* 2014; 66:148–54.
49. Kekitiinwa A, Musiime V, Thomason MJ, et al. Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children. *Antivir Ther* 2016; 21: 579–85.
50. Turkova A, Waalewijn H, Chan MK, et al. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. *Lancet HIV* 2022; 9:e627–37.



## CONFIDENCE IN DOVATO ACROSS TREATMENT SETTINGS<sup>4-9</sup>

Treatment-naïve resistance rates, with up to **3 years of evidence**<sup>5-7</sup>

**0%**  
(n=0/1,885)<sup>\*4</sup>  
REAL-WORLD EVIDENCE

**0.1%**  
(n=1/953)<sup>\*\*1,1,5,5-7</sup>  
RANDOMISED CONTROLLED TRIALS

Treatment-experienced resistance rates, with up to **5 years of evidence**<sup>1-3</sup>

**0.03%**  
(n=10/35,888)<sup>\*4</sup>  
REAL-WORLD EVIDENCE

**0%**  
(n=0/615)<sup>†1,5,8,9</sup>  
RANDOMISED CONTROLLED TRIALS

## >300,000 PEOPLE LIVING WITH HIV HAVE BEEN TREATED WITH DOVATO GLOBALLY<sup>10</sup>

DOVATO is supported by a wealth of evidence, with the outcomes of **>40,000** people living with HIV captured within clinical trials and real-world evidence, including those with:<sup>4-9,11,12</sup>



**NO PRIOR TREATMENT EXPERIENCE<sup>13</sup>**



**NO BASELINE RESISTANCE TESTING<sup>13</sup>**




**HIGH BASELINE VIRAL LOAD**  
(>100,000 copies/mL and even >1M copies/mL)<sup>6,13</sup>



**LOW CD4 + COUNT**  
(≤200 cells/mm<sup>3</sup>)<sup>13</sup>

■ Patients from phase III RCTs

■ Patients from unique real-world cohorts



## IS IT TIME TO RECONSIDER THE VALUE OF THE 2<sup>ND</sup> NRTI?

LEARN MORE

DOVATO is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.<sup>13</sup>

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK on 0800 221441

### REFERENCES

- Maggiolo F et al. BMC Infect Dis 2022; 22(1): 782.
- Taramasso L et al. AIDS Patient Care STDS 2021; 35(9): 342-353.
- Ciccullo A et al. JAIDS 2021; 88(3): 234-237.
- ViiV Healthcare. Data on File. REF-223795. 2024.
- Cahn P et al. AIDS 2022; 36(1): 39-48.
- Rolle C et al. Open Forum Infect Dis 2023; 10(3): ofad101.
- Cordova E et al. Poster presented at 12th IAS Conference on HIV Science. 23-26 July 2023. Brisbane, Australia. TUPEB02.
- De Wit S et al. Slides presented at HIV Glasgow. 23-26 October 2022. Virtual and Glasgow, UK. M041.
- Llibre J et al. Clin Infect Dis 2023; 76(4): 720-729.
- ViiV Healthcare. Data on File. REF-220949. 2024.
- Rolle C et al. Poster presented IDWeek. 11-15 October 2023. Virtual and Boston, USA. 1603.
- Slim J et al. Abstract presented IDWeek. 11-15 October 2023. Virtual and Boston, USA. 1593.
- DOVATO. Summary of Product Characteristics. June 2023.

### PRESCRIBING INFORMATION

[Dovato Prescribing Information](#)

[Legal Notices](#)

[Privacy Policy](#)

[Contact Us](#)

ViiV Healthcare, 980 Great West Road, Brentford, Middlesex, London, UK.

ViiV trademarks are owned by or licensed to the ViiV Healthcare group of companies.

Non-ViiV trademarks are owned by or licensed to their respective owners or licensors.

©2024 ViiV Healthcare group of companies or its licensor. All rights reserved.

Intended for healthcare professionals only.

### ABBREVIATIONS

**3TC**, lamivudine; **CD4**, cluster of differentiation 4; **DTG**, dolutegravir; **FDA**, United States Food and Drug Administration; **FTC**, emtricitabine; **HIV**, human immunodeficiency virus; **ITT-E**, intention-to-treat exposed; **NRTI**, nucleoside/nucleotide reverse transcriptase inhibitor; **RCT**, randomised controlled trial; **RNA**, ribonucleic acid; **TAF**, tenofovir alafenamide fumarate; **TDF**, tenofovir disoproxil fumarate; **XTC**, emtricitabine.

### FOOTNOTES

\*Data extracted from a systematic literature review of DTG+3TC real-world evidence. Overlap between cohorts cannot be fully excluded.

\*\*The reported rate reflects the sum-total of resistance cases calculated from GEMINI I and II (n=1/716, through 144 weeks), STAT (n=0/131, through 52 weeks), and D2ARLING (n=0/106, through 24 weeks).<sup>5-7</sup>

†GEMINI I and II are two identical 148-week, phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority, controlled clinical trials testing the efficacy of DTG/3TC in treatment-naïve patients. Participants with screening HIV-1 RNA ≤500,000 copies/mL were randomised 1:1 to once-daily DTG/3TC (n=716, pooled) or DTG + TDF/FTC (n=717, pooled). The primary endpoint of each GEMINI study was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 48 (ITT-E population, snapshot algorithm).<sup>13</sup>

‡STAT is a phase IIIb, open-label, 48-week, single-arm pilot study evaluating the feasibility, efficacy, and safety of DTG/3TC in 131 newly diagnosed HIV-1 infected adults as a first line regimen. The primary endpoint was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 24.<sup>6</sup>

§D2ARLING is a randomised, open-label, phase IV study designed to assess the efficacy and safety of DTG/3TC in treatment-naïve people with HIV with no available baseline HIV-1 resistance testing. Participants were randomised in a 1:1 ratio to receive DTG/3TC (n=106) or DTG + TDF/XTC (n=108). The primary endpoint was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 48.<sup>7</sup> Results at week 24 of the study.

|| The reported rate reflects the sum-total of resistance cases calculated from TANGO (n=0/369, through 196 weeks) and SALSA (n=0/246, through 48 weeks).<sup>8,9</sup>

¶TANGO is a randomised, open-label, trial testing the efficacy of DOVATO in virologically suppressed patients. Participants were randomised in a 1:1 ratio to receive DOVATO (n=369) or continue with TAF-containing regimens (n=372) for up to 200 weeks. At Week 148, 298 of those on TAF-based regimens switched to DOVATO. The primary efficacy endpoint was the proportion of subjects with plasma HIV-1 RNA ≥50 copies/mL (virologic non-response) as per the FDA Snapshot category at Week 48 (adjusted for randomisation stratification factor).<sup>8,13</sup>

#SALSA is a phase III, randomised, open-label, non-inferiority clinical trial evaluating the efficacy and safety of switching to DTG/3TC compared with continuing current antiretroviral regimens in virologically suppressed adults with HIV. Eligible participants were randomised 1:1 to switch to once-daily DTG/3TC (n=246) or continue current antiretroviral regimens (n=247). The primary endpoint was the proportion of subjects with plasma HIV-1 RNA ≥50 copies/mL at Week 48 (ITT-E population, snapshot algorithm).<sup>9</sup>